NCT07270120Not yet recruitingPhase 1
Senolytics for Secondary Progressive MS
Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 15 Jan 2026
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Ohio State University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07270120
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- From 15 Jan 2026 to the primary completion date, 15 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drug or alcohol abuse in the previous 5 years
- Use of drugs metabolized by the same liver enzymes as D or Q
Other illness
- Unstable coronary artery disease (myocardial infarction within 6 months or angina)
- Stroke or transient ischemic attack in the past 6 months
- Pulmonary arterial hypertension
- Current or chronic history of liver disease
- Alzheimer's or Parkinson's disease
- History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage
- History of angina or myocardial infarction, arrhythmia, or heart failure at any time
- Chronic renal disease (glomerular filtration rate \< 30 mL/min/1.73 m2)
Lab values
- QTc prolongation
- Anemia (Hgb\<9), thrombocytopenia (platelets\<50,000 per microliter), or neutropenia (ANC\< 1000 per microliter)
- Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L)
- ALT/AST \>1.5x ULN, total bilirubin \>ULN, and alkaline phosphatase \>2x ULN
- Anti-arrhythmic medications known to cause QTc prolongation
- Anti-platelet or anti-coagulant medications other than aspirin
Other
- Hospitalization within 6 months
- Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women
- Antipsychotics and anxiolytics
- Quinolone antibiotics
- Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg/sperm
- Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort
Who the study is looking for
- Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria
- Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.
- Evidence of MS progression over the past 12 months.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State Martha Morehouse Outpatient Care Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.